Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | GLA | P06280 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9646602 | 0.85 | KDM4E (0.59) | KDM4EALDH1A1GLAGAALMNA | |
| SCHEMBL516525 | 0.84 | KDM4E (0.58) | KDM4EALDH1A1GLAGAALMNA | |
| SCHEMBL115719 | 0.83 | KDM4C (0.53) | KDM4EALDH1A1GLAGAAKMT2A | |
| SCHEMBL30578227 | 0.83 | KDM4C (0.53) | KDM4EALDH1A1GLAGAAKMT2A | |
| SCHEMBL459318 | 0.83 | KDM4E (0.47) | KDM4EALDH1A1GLAGAALMNA | |
| SCHEMBL23012324 | 0.83 | KDM4E (0.57) | KDM4EALDH1A1GLAGAALMNA | |
| SCHEMBL17462368 | 0.83 | ALDH1A1 (0.45) | KDM4EALDH1A1GLAGAALMNA | |
| SCHEMBL22717408 | 0.82 | SLC22A12 (0.56) | KDM4EALDH1A1GLAGAALMNA | |
| SCHEMBL31119793 | 0.82 | SLC22A12 (0.56) | KDM4EALDH1A1GLAGAALMNA | |
| SCHEMBL31006669 | 0.82 | SLC22A12 (0.56) | KDM4EALDH1A1GLAGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073475-A9 | CEREBLON LIGANDS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2024073475-A1 | CEREBLON LIGANDS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A PROTEOVANT THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-3938364-B1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | ALTERITY THERAPEUTICS LTD (AU) | 2023-08-23 | — | — | EP | disclosed |
| EP-3938364-B1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | ALTERITY THERAPEUTICS LTD (AU) | 2023-08-23 | — | — | EP | disclosed |
| EP-4168408-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2023-04-26 | — | — | EP | disclosed |
| CN-115667256-A | Compounds for treating diseases and methods of treating diseases | 艾特里提治疗有限公司 | 2023-01-31 | — | — | CN | disclosed |
| EP-3938364-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2022-01-19 | — | — | EP | disclosed |
| WO-2021253091-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021253091-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2021-12-23 | — | — | WO | disclosed |
| CN-113811533-A | Compounds and methods for treating diseases | 艾特里提治疗有限公司 | 2021-12-17 | — | — | CN | disclosed |
| EP-2482660-A1 | COMPOSITION AND METHOD FOR CONTROLLING ARTHROPOD PESTS | Sumitomo Chemical Co., Ltd (JP) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011049223-A1 | COMPOSITION AND METHOD FOR CONTROLLING ARTHROPOD PESTS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011040629-A1 | COMPOSITION AND METHOD FOR CONTROLLING ARTHROPOD PESTS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-04-07 | — | — | WO | disclosed |
| US-7855201-B2 | Morpholine carboxamide prokineticin receptor antagonists | Merck Sharp & Dohme. Corp. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20090306076-A1 | Morpholine Carboxamide Prokineticin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-12-10 | — | — | US | disclosed |
| EP-1959959-A2 | MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007067511-A2 | MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-4725606-A | AUTOIMMUNE DISEASES | MERCK & CO., INC. (US) | 1988-02-16 | — | — | US | disclosed |
| US-4697012-A | IMMUNOLOGY, ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. (US) | 1987-09-29 | — | — | US | disclosed |
| US-4089960-A | Antiemetic, psychosomatic and antipsychotic heterocyclic pyridine carboxamides | CIBA-GEIGY CORPORATION (US) | 1978-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306076-A1 | Morpholine Carboxamide Prokineticin Receptor Antagonists | PROKR2, PROKR1, NTSR2 | KDM4E 4734/4885ALDH1A1 4629/4885GLA 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.